SMMT Insider Trading Activity and SEC Form 4 Filings
SMMT insider trading summary
Over the past 12 months, insiders at Summit Therapeutics Inc. (SMMT) reported 6 open-market purchases worth $103.6M by 3 insiders and no sales on SEC Form 4. Net insider buying was $103.6M.
Latest SMMT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Mahkam Zanganeh | Co-Chief Executive Officer | Buy | $50.0M (3,810,000 @ $13.12) |
| Jun 12, 2026 | Robert W Duggan | Co-Chief Executive Officer | Buy | $50.0M (3,810,000 @ $13.12) |
| Jun 4, 2026 | Manmeet Singh Soni | COO and CFO | Buy | $361K (25,000 @ $14.43) |
| Jun 4, 2026 | Mahkam Zanganeh | Co-Chief Executive Officer | Buy | $1.5M (100,000 @ $14.60) |
| Jun 4, 2026 | Robert W Duggan | Co-Chief Executive Officer | Buy | $1.5M (100,000 @ $14.60) |
| Jun 4, 2026 | Manmeet Singh Soni | COO and CFO | Buy | $362K (25,000 @ $14.46) |
| Oct 21, 2025 | Yu Xia | Director | Buy | $10.0M (533,617 @ $18.74) |
| Oct 21, 2025 | Robert W Duggan | Co-Chief Executive Officer | Buy | $500K (26,680 @ $18.74) |
| Oct 21, 2025 | Mahkam Zanganeh | Co-Chief Executive Officer | Buy | $500K (26,680 @ $18.74) |
| Sep 11, 2025 | Robert W Duggan | Co-Chief Executive Officer | Buy | $90K (5,000 @ $18.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.